Chad Tang1, Xiudong Lei2, Grace L Smith3, Hubert Y Pan1, Kenneth Hess4, Aileen Chen3, Karen E Hoffman1, Brian F Chapin5, Deborah A Kuban1, Mitchell Anscher1, Ya-Chen Tina Shih2, Steven J Frank1, Benjamin D Smith6. 1. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 2. Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 3. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. 4. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas. 5. Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, Texas. 6. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas; Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, Texas. Electronic address: bsmith3@mdanderson.org.
Abstract
PURPOSE: Recent trends in payer and patient preferences increasingly incentivize time-efficient (≤2-week treatment time) prostate cancer treatments. METHODS AND MATERIALS: National Medicare claims from January 1, 2011, through December 31, 2014, were analyzed to identify newly diagnosed prostate cancers. Three "radical treatment" cohorts were identified (prostatectomy, brachytherapy, and stereotactic body radiation therapy [SBRT]) and matched to an active surveillance (AS) cohort by using inverse probability treatment weighting via propensity score. Total costs at 1 year after biopsy were calculated for each cohort, and treatment-specific costs were estimated by subtracting total 1-year costs in each radical treatment group from those in the AS group. RESULTS: Mean 1-year adjusted costs were highest among patients receiving SBRT ($26,895), lower for prostatectomy ($23,632), and lowest for brachytherapy ($19,980), whereas those for AS were $9687. Costs of radical modalities varied significantly by region, with the Mid-Atlantic and New England regions having the highest cost ranges (>$10,000) and the West South Central and Mountain regions the lowest range in costs (<$2000). Quantification of toxic effects showed that prostatectomy was associated with higher genitourinary incontinence (hazard ratio [HR] = 10.8 compared with AS) and sexual dysfunction (HR = 3.5), whereas the radiation modalities were associated with higher genitourinary irritation/bleeding (brachytherapy HR = 1.7; SBRT HR = 1.5) and gastrointestinal ulcer/stricture/fistula (brachytherapy HR = 2.7; SBRT HR = 3.0). Overall mean toxicity costs were highest among patients treated with prostatectomy ($3500) followed by brachytherapy ($1847), SBRT ($1327), and AS ($1303). CONCLUSIONS: Time-efficient treatment techniques exhibit substantial variability in toxicity and costs. Furthermore, geographic location substantially influenced treatment costs.
PURPOSE: Recent trends in payer and patient preferences increasingly incentivize time-efficient (≤2-week treatment time) prostate cancer treatments. METHODS AND MATERIALS: National Medicare claims from January 1, 2011, through December 31, 2014, were analyzed to identify newly diagnosed prostate cancers. Three "radical treatment" cohorts were identified (prostatectomy, brachytherapy, and stereotactic body radiation therapy [SBRT]) and matched to an active surveillance (AS) cohort by using inverse probability treatment weighting via propensity score. Total costs at 1 year after biopsy were calculated for each cohort, and treatment-specific costs were estimated by subtracting total 1-year costs in each radical treatment group from those in the AS group. RESULTS: Mean 1-year adjusted costs were highest among patients receiving SBRT ($26,895), lower for prostatectomy ($23,632), and lowest for brachytherapy ($19,980), whereas those for AS were $9687. Costs of radical modalities varied significantly by region, with the Mid-Atlantic and New England regions having the highest cost ranges (>$10,000) and the West South Central and Mountain regions the lowest range in costs (<$2000). Quantification of toxic effects showed that prostatectomy was associated with higher genitourinary incontinence (hazard ratio [HR] = 10.8 compared with AS) and sexual dysfunction (HR = 3.5), whereas the radiation modalities were associated with higher genitourinary irritation/bleeding (brachytherapy HR = 1.7; SBRT HR = 1.5) and gastrointestinal ulcer/stricture/fistula (brachytherapy HR = 2.7; SBRT HR = 3.0). Overall mean toxicity costs were highest among patients treated with prostatectomy ($3500) followed by brachytherapy ($1847), SBRT ($1327), and AS ($1303). CONCLUSIONS: Time-efficient treatment techniques exhibit substantial variability in toxicity and costs. Furthermore, geographic location substantially influenced treatment costs.
Authors: Brent K Hollenbeck; Maggie J Bierlein; Samuel R Kaufman; Lindsey Herrel; Ted A Skolarus; David C Miller; Vahakn B Shahinian Journal: Am J Manag Care Date: 2016-09 Impact factor: 2.229
Authors: James B Yu; Laura D Cramer; Jeph Herrin; Pamela R Soulos; Arnold L Potosky; Cary P Gross Journal: J Clin Oncol Date: 2014-03-10 Impact factor: 44.544
Authors: Yunjie Song; Jonathan Skinner; Julie Bynum; Jason Sutherland; John E Wennberg; Elliott S Fisher Journal: N Engl J Med Date: 2010-05-12 Impact factor: 91.245
Authors: Nathan C Sheets; Gregg H Goldin; Anne-Marie Meyer; Yang Wu; YunKyung Chang; Til Stürmer; Jordan A Holmes; Bryce B Reeve; Paul A Godley; William R Carpenter; Ronald C Chen Journal: JAMA Date: 2012-04-18 Impact factor: 56.272
Authors: J L Donovan; F C Hamdy; J A Lane; D E Neal; M Mason; C Metcalfe; E Walsh; J M Blazeby; T J Peters; P Holding; S Bonnington; T Lennon; L Bradshaw; D Cooper; P Herbert; J Howson; A Jones; N Lyons; E Salter; P Thompson; S Tidball; J Blaikie; C Gray; P Bollina; J Catto; A Doble; A Doherty; D Gillatt; R Kockelbergh; H Kynaston; A Paul; P Powell; S Prescott; D J Rosario; E Rowe; M Davis; E L Turner; R M Martin Journal: N Engl J Med Date: 2016-09-14 Impact factor: 91.245
Authors: James B Yu; Pamela R Soulos; Jeph Herrin; Laura D Cramer; Arnold L Potosky; Kenneth B Roberts; Cary P Gross Journal: J Natl Cancer Inst Date: 2012-12-14 Impact factor: 13.506
Authors: Parth K Modi; Samuel R Kaufman; Ji Qi; Brian R Lane; Michael L Cher; David C Miller; Brent K Hollenbeck; Vahakn B Shahinian; James M Dupree Journal: Urology Date: 2018-07-07 Impact factor: 2.649
Authors: Jeremiah W Sanders; Steven J Frank; Rajat J Kudchadker; Teresa L Bruno; Jingfei Ma Journal: Magn Reson Med Date: 2019-02-08 Impact factor: 4.668
Authors: Chad Tang; Xiudong Lei; Grace L Smith; Hubert Y Pan; Karen E Hoffman; Rachit Kumar; Brian F Chapin; Ya-Chen Tina Shih; Steven J Frank; Benjamin D Smith Journal: Int J Radiat Oncol Biol Phys Date: 2020-12-13 Impact factor: 7.038